This review surveys the evidence that neuropeptides like CRF, neuropeptide Y, oxytocin, and substance P play key roles in mood disorders and could be targets for new psychiatric medications.
11 neuropeptide systems linked to mood disordersIncluding CRF, neuropeptide Y, oxytocin, substance P, and galanin — each representing a potential target for new psychiatric drugs
What the researchers found
The review identifies multiple neuropeptide systems involved in mood regulation: corticotropin-releasing factor (CRF) and its related urocortins drive the stress response and are overactive in depression; neuropeptide Y appears to be protective against anxiety and stress; oxytocin has anxiolytic properties; substance P (via NK1 receptors) promotes anxiety and emotional distress; neuropeptide S promotes wakefulness and reduces anxiety; and PACAP modulates stress responses.
The central argument is that because current monoamine-targeting drugs fail a significant proportion of patients, these neuropeptide systems represent promising alternative or complementary therapeutic targets.
Why it matters
Depression is the leading cause of disability worldwide, and a large percentage of patients don't improve with existing medications. Understanding how neuropeptides contribute to mood disorders opens entirely new avenues for drug development. Rather than tweaking serotonin or norepinephrine levels, future treatments could target the brain's peptide signaling systems more directly.
How the study worked
This is a narrative review article summarizing published research from animal models of mood disorders (including genetically modified rodent models), preclinical pharmacology studies, and available clinical data across 11 neuropeptide systems.
What this study cannot tell us
Most evidence cited comes from animal models, which don't perfectly replicate human psychiatric conditions. The review was published in 2013 and doesn't cover more recent clinical trials targeting these neuropeptide systems. The complexity of neuropeptide interactions makes it difficult to predict which targets will prove most clinically useful.
How to read the evidence
This is a narrative review synthesizing primarily animal research with some clinical data. It provides a strong theoretical framework but does not present original clinical trial evidence.
When this study was published
Published in 2013, this review provides important background context. Some neuropeptide drug targets discussed have since progressed to clinical trials, while others have stalled — readers should seek updated reviews for current status.
The bigger picture
Since this 2013 review, several neuropeptide-targeting drugs have advanced in development. NK1 receptor antagonists (targeting substance P) reached clinical trials for depression, CRF receptor antagonists were tested for anxiety disorders, and intranasal oxytocin has been studied for social anxiety and PTSD. This review provides the foundational rationale for that translational work.
Questions still open
- Which of the 11 neuropeptide systems reviewed has the most clinical promise for treating treatment-resistant depression?
- Can neuropeptide-targeting drugs work alongside existing antidepressants to improve response rates?
- Why have neuropeptide-targeted drugs faced challenges in clinical translation despite strong animal data?
Common questions
What are neuropeptides and how are they different from neurotransmitters?
Why don't we already have neuropeptide-based antidepressants?
Read the original research
Role of neuropeptides in anxiety, stress, and depression: from animals to humans.
Neuropeptides, 47(6), 401-19
Citation
Kormos, Viktória; Gaszner, Balázs. (2013). Role of neuropeptides in anxiety, stress, and depression: from animals to humans.. Neuropeptides, 47(6), 401-19. https://doi.org/10.1016/j.npep.2013.10.014